Inventiva announces exercise of option by Boehringer Ingelheim

The move follows the successful validation of a new fibrosis target and triggers a milestone payment of €2.5m to Inventiva under the terms of the agreement, Inventiva is eligible to receive research funding and milestone payments of up to €170m and tiered royalty payments

Inventiva, a French biopharmaceutical company developing innovative therapies, particularly for the treatment of fibrotic diseases, announced the exercise of an option by Boehringer Ingelheim advancing the collaboration, which began in May 2016.

Pierre Broqua, CSO and Co-Founder of Inventiva, said: “We are very pleased with this decision by Boehringer Ingelheim, which underscores the research capabilities developed by Inventiva in fibrosis and excited to develop this new idiopathic pulmonary fibrosis (IPF) approach with Boehringer Ingelheim, a partner offering the research, development and commercial expertise needed to develop breakthrough therapies for patients suffering from fibrotic diseases such as IPF.”

The joint research team has validated a new fibrosis target and data generated in the programme supports its therapeutic potential in fibrotic conditions and IPF and has been selected as the first indication to be investigated. Boehringer Ingelheim’s execution of this option triggers a milestone payment to Inventiva of €2.5 million.

Clive Wood, Senior Corporate VP Discovery Research at Boehringer Ingelheim, said: “We are excited about moving this very productive and highly interactive collaboration forward, which combines Inventiva’s strong competency and know-how in the field of transcriptional regulation and fibrosis with Boehringer Ingelheim’s expertise in the discovery and development of treatments for fibrotic diseases like IPF. This collaboration with Inventiva is part of Boehringer Ingelheim’s comprehensive research and development focus on fibrotic diseases.”

Companies